Hepatocarcinoma: diagnóstico y resección con radiofrecuencia quirúrgica / HEPATOCARCINOMA: DIAGNOSIS AND RESECTION WITH SURGICAL RADIO FREQUENCY

Objetivo: Presentar metodología diagnostica y resección atípica, con fines curativos de hepatocarcinoma. Caso clínico: Femenina de 82 años, con múltiples antecedentes entre el que se destaca, hepatitis a virus C de 15 años de evolución, que presenta por estudios complementarios alta sospecha de hepatocarcinoma, se realiza laparotomía exploradora con resección atípica de tumor en segmento 5 y 6 con radiofrecuencia quirúrgica y colecistectomía con colangiografía intraoperatoria. Cursa post operatorio sin complicaciones con alta sanatorial al 8vo dia. Conclusion: Hay que sospechar esta patología en pacientes con antecedentes de hepatopatía viral, plantear screening adecuado para un diagnóstico temprano y la mejor resolución adaptada a cada paciente. Dentro de las opciones terapéuticas encontramos la radiofrecuencia quirúrgica como una buena herramienta, con índice bajo de complicaciones

Objective: To present diagnostic methodology and atypical resection, for curative purposes of hepatocarcinoma. Clinical case: An 82-year-old female, with multiple history factors, among them, hepatitis C virus of 15 years of evolution, which presents high suspicion of hepatocarcinoma due to complementary studies, exploratory laparotomy is performed with atypical resection of tumor in segments 5 and 6 with surgical radiofrequency and cholecystectomy with intraoperative cholangiography. Post-operative course without complications with sanatorial discharge on the 8th day. Conclusion: This pathology must be suspected in patients with history of viral liver disease. We suggest an adequate screening for an early diagnosis and the best resolution adapted to each patient. Among the therapeutic options we find surgical radiofrequency as a good tool, with a low rate of complications

Implicaciones de la microbiota intestinal en las enfermedades crónicas del hígado / Implications of the intestinal microbiota in the chronic liver diseases

RESUMEN La microbiota se refiere al conjunto de todos los de microorganismos que se localizan de manera normal en distintos sitios de los cuerpos de los seres vivos pluricelulares, tales como el cuerpo humano. Las modificaciones del eje intestino-hígado se ha convertido en la actualidad en un grave problema científico al haberse encontrado en diversas investigaciones, que esta microbiota está relacionada con el daño hepático con independencia de la causa de la lesión hepática. Se realizó una revisión sistemática sobre las implicaciones demamicrobiota intestinal en las enfermedades hepáticas. Se realizó una revisión de artículos científicos publicados entre 2012 y 2018 en diversas bases de datos en línea. Se presenta el conocimiento existente hasta el momento sobre la microbiota intestinal en pacientes portadores de enfermedades hepáticas, con hincapié en las hepatitis C y la cirrosis hepática. La composición de microbiota de intestino estuvo asociada con el perfil inflamatorio y marcadores de fibrosis hepática, las que mejoraron con el tratamiento de antivirales de acción directa aunque las medidas de permeabilidad intestinal e inflamación permanecían inalteradas. Se reporta mejoría de los pacientes portadores de hepatitis viral tipo C, con antivirales de acción directa la cual estuvo asociada con modificaciones de la microbiota intestinal, que se correlacionó con mejoría en la fibrosis e inflamación hepática, los avances en este campo abren nuevas perspectivas en la biomedicina (AU).

SUMMARY Microbiota refers to the whole of microorganisms located in a normal way in different places of the bodies of pluricelular living beings, like the human body. The modifications of the axis intestine-liver have become a serious scientific problem, because in different researches researchers have found that this microbiota is related to hepatic damage depending on the cause of this hepatic lesion. To carry out a systematic review on the implication of intestinal macrobiota in liver diseases. The scientific articles published in the period 2012-2018 in different databases on line were reviewed. A total of 26 bibliographic sources were used, original articles and reviews. The authors present knowledge existent up to the moment on intestinal microbiota in patients who have liver diseases, making emphasis on hepatitis C and hepatic cirrhosis. The composition of the intestine microbiota was associated to an inflammatory and markers of hepatic fibrosis that improved with the treatment of direct action antivirals although the measures of intestinal permeability and inflammation remained inalterably. It is reported an improvement of patients carriers of viral hepatitis type C with the use direct action retrovirals, what was linked to modifications in the intestinal microbiota, and correlated to an improvement of fibrosis and liver inflammation; the advances obtained in this field open new perspectives in biomedicine (AU).

Prevalence of hepatitis B and hepatitis C in patients of chronic kidney disease

Background: Patients of CKD are highly exposed to HBV and HCV because of multiple blood transfusions and exposure to contaminated equipments. Infections by HBV and HCV are significant cause of morbidity in CKD patients by causing liver damage and membranoproliferative GN. Present study was done to observe the prevalence of HBV and HCV in patients of CKD and to compare the prevalence of these infections in patients who were on maintenance haemodialysis and who were not on maintenance hemodialysis.Methods: This study had been conducted on 140 patients. Patients were diagnosed as having CKD on basis of Cockcroft-gault equation as per KDOQI guidelines. Stage 3, 4 or 5 patients were included for the study whereas patients with stage 1 or 2 were excluded. These 140 cases were divided into 2 groups, Group I included 70 cases who were on maintenance hemodialysis and Group II included 70 patients who were not on maintenance hemodialysis. The prevalence of HBV and HCV in the two groups was observed. Diagnosis of HBV was made by detection of HBsAg (one step immunoassay) and diagnosis of HCV was made by detection of antibodies to Hepatitis C(enzyme linked immunoassay). Prevalence data of NCDC was used for comparison with general population.Results: In Group I, 15 (21%) patients were positive for HCV and 9 (12.9%) were positive for HBV which is significantly higher compared to Group II patients in which 6 (8.6%) and 2 (2.9%) were positive respectively. Overall out of 140 patients,21(15%) were positive for HCV and 11(7.9%) were positive for HBV, which is significantly higher compared to data of NCDC for general population in which prevalence of HCV and HBV is 1% and 4% respectivelyConclusions: Prevalence of HBV and HCV was significantly higher in patients of CKD than the general population, which was further higher in patients who were on maintenance hemodialysis and have received multiple blood transfusions, emphasizing the need to implement the methods to limit the spread of HBV and HCV.

Seroprevalence Of Transfusion Transmissible Infections Among Blood Donors In A Tertiary Care Centre: Eight Years Study

Background:Transfusion transmissible infections (TTIs) are one of the major adverse effects of blood transfusion. Serological testing can reduce, but not eliminate the occurrences of TTIs. Study of TTIs amongst blood donors could help to find safe blood for the patients.Aims:This study was conducted to evaluate the prevalence of markers of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV), Syphilis and Malaria among Voluntary Blood Donors and Replacement Blood Donors in a tertiary care centre.Materials and Methods: Aretrospective study was conducted at The State of the art Model blood bank, Pt. Jawaharlal Nehru Memorial Medical College (JNMMC) and Dr. B. R. Ambedkar Memorial Hospital, Raipur, Chhattisgarh. This study included all the blood donors both from in-hospital donations and outdoor camps donations (including Voluntary and Replacement donors) from January 2011 to December 2018. Enzyme-linked immunosorbent assay (ELISA) test was done for screening of HBV, HCVand HIV; Rapid Plasma Reagin (RPR) test was done for syphilis and Card Test for Malaria Antigen.Results:Atotal of 1,08,577 donors were screened over a period of eight years. The seroprevalence of HIV, HBV, HCV, syphilis and malaria was found to be 0.12%, 0.77%, 0.04%, 0.22% and 0.03% respectively. Overall seroprevalence of reactive TTIs was 1.19%, which was maximum in the year 2013 (2.28%) after that there was a gradual decrease in the prevalence rate of TTIs in blood donors over the years. Infections were more common among Replacement Donors as compared to Voluntary Donors. Conclusion: The increase in public awareness regarding Voluntary blood donation, meticulous donor screening, counselling and use of highly sensitive tests can help in reducing the risk of TTIs. Prevalence of HIVinfection is decreasing in the blood donors. The HBVinfection still remains a menace to be tackled. HCV, Syphilis and malaria maintain a low rate of positivity. Methods to ensure a safe blood supply should be encouraged.

Hepatitis C ¿cuándo tratar? / Hepatitis C: when to treat?

Chronic hepatitis C virus infection is a disease of low endemicity in Chile, but with high personal and health costs due to its associated complications. A radical change during the last decades in the treatment of this disease has been the appearance of direct action antivirals that changed the history of the disease, reducing the progression to liver cirrhosis, complications, need for liver transplantation or death. This review describes the general indications for the treatment of hepatitis C virus infection, contraindications and the different special scenarios.

La infección crónica por virus hepatitis C es una enfermedad de baja endemicidad en Chile, pero que ocasiona altos costos personales y sanitarios por sus complicaciones asociadas. Un cambio radical durante las últimas décadas en el tratamiento de esta enfermedad ha sido la aparición de los antivirales de acción directa que han cambiado la historia de la enfermedad, reduciendo la progresión a cirrosis hepática, complicaciones, necesidad de trasplante hepático o muerte. En esta revisión se describirán las indicaciones generales de tratamiento de la infección por virus hepatitis C, contraindicaciones y los diferentes escenarios especiales presentes en la práctica clínica.

Nuevas perspectivas en el tratamiento farmacológico de la Hepatitis C / New perspectives in the pharmacological treatment of Hepatitis C

Introducción: La infección por el virus de la hepatitis C (VHC) es una de las principales causas de enfermedad hepática a nivel mundial. Alrededor de 60-80 por ciento de los infectados sufren una infección crónica pudiendo desarrollar otras patologías hepáticas como cirrosis y hepatocarcinoma. El tratamiento contra el VHC ha experimentado un enorme avance en la última década, cuya culminación ha llegado con la aparición de los Agentes Antivirales Directos (AAD) que han conseguido obtener tasas de curación superiores a 90 por ciento. Objetivo: Describir los diferentes mecanismos de acción de los AAD, además de contrastar los principales ensayos clínicos que están actualmente en desarrollo, hacer recomendaciones acerca de las opciones de tratamiento disponibles y perfilar los cambios que van a tener lugar en el tratamiento farmacológico de la Hepatitis C. Material y Métodos: Se realizaron varias búsquedas sistemáticas en la base de datos Pubmed, en los artículos expuestos en el Congreso The liver meeting en noviembre de 2014 de la AASLD (American Association for the Study of Liver Diseases), así como en la guía de la EASL (European Association for the Study of the Liver). Desarrollo: La llegada de nuevos fármacos con nuevas estrategias terapéuticas están incrementando la complejidad de la terapia, por ello es necesario conocer estos nuevos fármacos y sus posibles combinaciones. Conclusiones: Los excelentes resultados de la terapia con AAD han producido un intenso cambio en las recomendaciones terapéuticas, al permitir terapias de menor duración, mejor toleradas y de mayor seguridad(AU)

Introduction: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90 percent. Objective: To know the different available treatments options as well as which will be available in a near future. Materials and methods: Several systematic searches were made in the PubMed database; in the articles from the liver meeting congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide. Development: The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations. Conclusions: The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health(AU)

Prevalence of Hepatitis B and C in Donated Blood from the Jazan Region of Saudi Arabia

Background: Infections caused by the hepatitis B virus (HBV) and the hepatitis C virus (HCV) are global public health problems. The safety of donated blood can be estimated by monitoring the prevalence of viral markers in the donor population. The present study was carried out in the Jazan region to determine the prevalence of HBV and HCV among Saudi blood donors. Methods: Over a period of six years (January 2004 to December 2009), a total of 29 949 blood units were collected from healthy voluntary and replacement native Saudi blood donors. The donated units were serologically screened for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and antibody to hepatitis C virus (anti-HCV). These data were then analysed. Results: HBsAg was positive in 3.8% of the blood units that were collected, the blood units with anti–HCV seropositivity had the lowest prevalence (0.41%), and the prevalence of HBsAg was highest in the group that was > 46 years of age. A significant decline in the prevalence of HBV infection has been observed, from 5.6% in 2004 to 2.3% in 2009 (P < 0.001). Conclusion: The present study showed that the prevalence of HBV and HCV was in a significant decline from 2004 to 2009, and the prevalence of HBsAg and anti-HCV significantly increased with age.

HCV: similitudes y diferencias con el HIV / HCV: similarities and differences with HIV

El virus de la hepatitis C (HCV) ha sido caracterizado en profundidad a nivel molecular en la última década. La partícula viral envuelta alberga una nucleocápside, estructura constituida principalmente por una proteína básica que está en estrecha interacción con el genoma viral representado por una molécula de ARN de cadena simple con polaridad positiva. La organización genómica del HCV es similar a la de Pestivirus y Flavivirus. Diferentes receptores celulares se han postulado en su participación para el ingreso del virus a la célula blanco. Su estrategia de multiplicación deja avizorar los blancos de acción de nuevas drogas para controlar la replicación. Si bien comparte con el HIV - desde su naturaleza de ARN virus - entre otras características virológicas la magnífica plasticidad genómica, otras por el contrario revisten claras diferencias. Ambos virus constituyen un enorme desafío en Salud

The hepatitis C virus (HCV) has been deeply characterized at molecular level during the last decade. The enveloped viral particle protects the nucleocapsid that is essentially constituted by a basic protein that interacts with the viral genome, a single strand RNA with positive polarity. The genomic organization of the HCV is similar to the Pestivirus and Flavivirus. Different cellular receptors have been postulated to play a role to the virus entry in the cellular target. The replication strategy exhibit the different plausible target of antiviral action with new drugs in order to control the replication. The HCV shares with the HIV the vast genomic plasticity because both are RNA viruses but other characteristics are different between them. Both viruses are an enormous trial for human health

Hepatocarcinoma y trombosis portal diagnosticados por ecografía y tomografía computada en pacientes cirróticos chilenos en un hospital público, 2004 - 2011 / Hepatocellular carcinoma and portal vein thrombosis diagnosed by sonography and ct scan in chilean cirrhotic patients between 2004 and 2011

There is no available data on prevalence of hepatocellular carcinoma (HCC) and portal thrombosis (PT) in Chilean cirrhotic patients. Objectives: To evaluate the development of these entities and the role ultrasound (US) may play as the imaging method of choice in their diagnostic approach. Material and methods: A cohort study of patients with diagnosis of cirrhosis by US or CT scans between 2004 and 2008. We evaluated both demographic and clinical records, along with disease development until 2011, by performing a retrospective review of their imaging findings. We investigated whether patients presented HCC and / or PT as detected by US / CT studies. Results: Two hundred and eleven (211) patients with an average age of 62.6 years were included. HCC was diagnosed in 10.4 percent of cases, whilst PT was observed in 4.3 percent of patients. A 33 percent of PT occurred in association with HCC and exhibited worse survival rates. Ultrasonographic studies yielded suspicious results in a significant percentage of cases, thus CT scans were performed to confirm the diagnosis. Conclusions: Ultrasound examination appears to be a useful tool for detecting complications of cirrhosis.

No existen datos en pacientes cirróticos chilenos de prevalencia de hepatocarcinoma(CHC) y trombosis portal(TP). Objetivos: Evaluar el desarrollo de estas complicaciones y el rol que podría jugar el ultrasonido (US) como primer método de imagen en su aproximación diagnóstica. Material y métodos: Estudio de cohorte en pacientes diagnosticados mediante US o TC de cirrosis entre 2004 y 2008. Se evaluaron datos demográficos, clínicos, y su evolución hasta 2011, realizando revisión retrospectiva de sus estudios imagenológicos. Se investigó si presentaron HCC y/o TP que fueran detectados mediante US/TC. Resultados: Se incluyeron 211 pacientes, con un promedio de 62,6 años. En el 10,4 por ciento se diagnosticó HCC y en el 4,3 por ciento TP. El 33 por ciento de TP ocurrieron asociadas a CHC y determinaron peor sobrevida. El US fue sospechoso en un porcentaje significativo de los casos, motivando la realización de TC confirmatoria. Conclusiones: El US aparece como una herramienta útil para la detección de complicaciones de cirrosis.

Detección de ARN de virus hepatitis C en la saliva de un grupo de pacientes con hepatitis C crónica / Detection of hepatitis C virus RNA in saliva of a group of patients with chronic hepatitis C

La Hepatitis C constituye un problema de salud pública y su transmisión está claramente asociada con la ruta parenteral. Sin embargo su agente causal, Virus de Hepatitis C (VHC), también ha sido aislado de otros fluidos incluyendo la saliva, aunque la relación existente entre VHC y la patología bucal no está completamente dilucidada. El objetivo del presente estudio fue determinar la presencia de ARN-VHC en la saliva de pacientes con Hepatitis C crónica. En la presente investigación se evaluaron 24 pacientes provenientes del Departamento de Hepatología del Hospital Clínico Universitario, Universidad Central de Venezuela, con infección por VHC. 5 ml de saliva no estimulada fue tomada de cada paciente. ARN-VHC fue detectada por la técnica de Transcriptasa Reversa- Reacción en cadena de la Polimerasa (TR-RCP). En 29 por ciento, (7/24) pacientes VHC+, se observó la presencia de ARN-VHC en saliva. En este estudio, observamos la presencia de ARN-VHC en la saliva de pacientes con infección crónica por VHC. Es necesario realizar estudios epidemiológicos a gran escala, para clarificar el significado biológico de la presencia de este agente viral en la saliva, incluyendo la potencial vía de transmisión por la exposición con este fluido

Hepatitis C is a worldwide public health problem and its transmisión is clearly associated with the parenteral route, however, the virus has also been isolated from other body fluids, including saliva, although the relationship between HCV and oral pathology is not clearly understood. The aim of this study was to determine the presence of HCV-RNA in saliva from patients with chronic C hepatitis. In the present investigation 24 patients, attended at the Hepatology Department, at the the Clinical Hospital University, Central University of Venezuela, with HCV infection were evaluated . 5ml of unstimulated saliva were taken of each patient. Saliva HCV-RNA was detected by Polymerase Chain Reaction (PCR). 29 percent (7/24) of HCV+ patients showed HCV-RNA in saliva. In this study, we observed the presence of HCV-RNA in saliva of patients infected with HCV. Further large-scale epidemiological studies are required to clarify the clinical significance of HCV in the saliva, including the potencial for viral transmisión through exposure to these fluids

Study on antitumor effect by gene immunization of the chimeric HBV and HCV / 中国免疫学杂志

Objective:To observe the specific cellular immune response and the protection against P815 mastovytoma cells(H 2 d) stable expressing HBV surface antigen and HCV core antigen after the immunized mice(H 2 d) with plasmids SpcDNA3.1,CpcDNA3.1 and chimeric plasmid CSpcDNA3.1.Methods:After subcutaneous immunization with the three plasmids SpcDNA3.1,CpcDNA3.1 and CSpcDNA3.1 respecitively 3 w,the mice were inoculated with the transfected P815 tumor cells.The tumors size and the survival rate were measured.CTL assay was detected with LDH methods.Results:The chimeric plasmid CSpcDNA3.1 could inhibit the tumor growth,prolong the survival period and improve the survivial rate evidently.The splencytes from immunized mice showed strong CTL activity to CSpcDNA3.1 transfected P815 tumor cells.Conclusion:It was suggestd that specific antitumor cellular immunity could be induced by immunization with the chimeric plasmid CSpcDNA3.1 that contain chimeric HBV and HCV gene.

Constructs and expression of hepatitis C virus core gene combined hepatitis B virus core gene with two multiple cloning sites vector / 中国免疫学杂志

Objective:To develop a HCV combined HBV DNA-based therapeutic vaccine.Methods:The HBV core gene and HCV core cDNA were inserted into the eukaryotic expression vector with two multiple cloning sites mammalian expression vector under the CMV promoter and RSC promoter respectively, named pRSC-HBV/HCV. Cellular expression of pRSC-HBV/HCV was assessed by Western blot and immunofluorescent study following transfection into SP2/0 cells. The Balb/c mice were immunized by multiple sites intramuscular injection with pRSC-HBV/HCV and the immune responses were detected.Results:The 21 kD and 14 kD core protein were observed. Both anti-HBc Ab and anti-HCV core Ab were detected in all immunized mice.Conclusion:The investigation demonstrated that pRSC-HBV/HCV could express HBcAg and HCV core protein, humoral immune response could be detected in mice immunized with pRSC-HBV/HCV.